Could Humanigen Stock Soar Even Higher After Its COVID Antibody Results?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·5 min read

Humanigen (NASDAQ: HGEN) recently announced impressive results from a late-stage study of its COVID-19 antibody therapy lenzilumab. The biotech stock skyrocketed on the news but subsequently gave up some of its gains. In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli talk about whether or not Humanigen stock could soar even higher going forward.